Доступ предоставлен для: Guest
Портал Begell Электронная Бибилиотека e-Книги Журналы Справочники и Сборники статей Коллекции
Critical Reviews™ in Oncogenesis
SJR: 0.631 SNIP: 0.503 CiteScore™: 2.2

ISSN Печать: 0893-9675
ISSN Онлайн: 2162-6448

Critical Reviews™ in Oncogenesis

DOI: 10.1615/CritRevOncog.v16.i1-2.50
pages 37-46

CREB and Leukemogenesis

Er-Chieh Cho
Division of Hematology/Oncology, Department of Pediatrics, David Geffen School of Medicine at UCLA, Los Angeles California
Bryan Mitton
Division of Hematology/Oncology, Department of Pediatrics, David Geffen School of Medicine at UCLA, Los Angeles California
Kathleen Sakamoto
Division of Hematology/Oncology, Department of Pediatrics, David Geffen School of Medicine at UCLA, Los Angeles California

Краткое описание

Acute myeloid leukemia (AML) is one of the most common leukemias with a 20% 5-year event-free survival in adults and 50% overall survival in children, despite aggressive chemotherapy treatment and bone marrow transplantation. The incidence and mortality rates for acute leukemia have only slightly decreased over the last 20 years, and therefore greater understanding of the molecular mechanisms associated with leukemic progression is needed. To this end, a number of transcription factors that appear to play a central role in leukemogenesis are being investigated; among them is the cAMP response element binding protein (CREB). CREB is a transcription factor that can regulate downstream targets involving in various cellular functions including cell proliferation, survival, and differentiation. In several studies, the majority of bone marrow samples from patients with acute lymphoid and myeloid leukemia demonstrate CREB overexpression. Moreover, CREB overexpression is associated with a poor outcome in AML patients. This review summarizes the role of CREB in leukemogenesis.

Ключевые слова: CREB, leukemia, oncogenesis, transcription factors

Articles with similar content:

Estrogen Receptor-β and the Insulin-Like Growth Factor Axis as Potential Therapeutic Targets for Triple-Negative Breast Cancer
Critical Reviews™ in Oncogenesis, Vol.20, 2015, issue 5-6
Diana Marquez-Garban, Yahya Elshimali, Edward B. Garon, Nalo Hamilton, Jaydutt Vadgama, Richard Pietras, David Elashoff, Vei H. Mah
TAM Receptors in Leukemia: Expression, Signaling, and Therapeutic Implications
Critical Reviews™ in Oncogenesis, Vol.16, 2011, issue 1-2
Justine Migdall-Wilson, Douglas K. Graham, Kristen Eisenman, Luis Brandao
Chemokines and Chemokine Receptors as Promoters of Prostate Cancer Growth and Progression
Critical Reviews™ in Eukaryotic Gene Expression, Vol.23, 2013, issue 1
Nicole Salazar, Miguel Castellan, Bal L. Lokeshwar, Samir S. Shirodkar
Clinical Significance of YY1 Overexpression in Human Hematopoietic Malignancies
Onco Therapeutics, Vol.1, 2010, issue 1-2
Silvana Canevari, Giancarlo Castellano, Sara Huerta-Yepez, Mario I. Vega, Ma del Lourdes Cabrera-Munoz, Clara M. Rivera Pazos, Loredana Militello, Haiming Chen, Massimo Libra, Stavroula Baritaki, Grazia Malaponte, James R. Berenson
Roles Each of Snail, Yin Yang 1, and RKIP in the Regulation of Tumor Cells Chemo- Immuno-Resistance to Apoptosis
Onco Therapeutics, Vol.4, 2013, issue 1
Sara Huerta-Yepez, Mario I. Vega, Ali R. Jazirehi, Stavroula Baritaki, Benjamin Bonavida